Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine in Autosomal Dominant Polycystic Kidney Disease
NCT06291116Phase 2Recruiting
- Sponsor
- Rouen University Hospital
- Start
- May 2026
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rotigotine in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Safety and Tolerability at 24 months. Started May 2026; status: recruiting.
02
Drugs
rotigotine
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06291116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291116.